Efficacy News and Research

RSS

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis, or inflammation of the blood vessels, a study has found.

1 Aug 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.

31 Jul 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout is a relatively common arthritic disease that affects about 4% (I in 25) of the population. It results from the deposition of uric acid in joints due to elevated blood levels and a resulting inflammation ensues which is very painful.

26 Jul 2013

Rapamycin extends mice lifespan but has limited effects on aging

The body's repair mechanisms begin to fail with increasing age. As a result, signs of wear and tear appear and the risk for many diseases, including Alzheimer's disease, diabetes, cardiovascular disorders and cancer, increases.

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

New technology enables all of the world's crops to take nitrogen from the air

A major new technology has been developed by The University of Nottingham, which enables all of the world's crops to take nitrogen from the air rather than expensive and environmentally damaging fertilisers.

26 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Silk implants placed in brain of animals may help stop progression of epilepsy

Silk has walked straight off the runway and into the lab. According to a new study published in the Journal of Clinical Investigation, silk implants placed in the brain of laboratory animals and designed to release a specific chemical, adenosine, may help stop the progression of epilepsy.

26 Jul 2013

Novo Solutions MD announces releases of NovoScarMD scar cream

Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury

25 Jul 2013

Studies support use of EOS 3D imaging system in assessing impact of bracing for AIS

EOS imaging, the pioneer in orthopaedic 2D/3D imaging, today announced that two new studies supporting the use of its 3D imaging technology in assessing the impact of bracing for adolescent idiopathic scoliosis have been published online in the European Spine Journal.

25 Jul 2013

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

Essentially, what an artificial pancreas would be doing is taking the blood glucose results from a continuous monitor and taking the data that the patient puts in about the amount she/he is eating, and then adjusting the amount of insulin being delivered by the pump based on a mathematical formula that would be very personalized to that patient.

25 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

A team of surgeons and members of the breast cancer program of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center is conducting a two-year pilot study of an innovative microsurgery technique coupled with imaging technology to not only prevent lymphedema but also potentially detect and treat it early.

24 Jul 2013

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

OracleBio, providers of high precision digital image analysis services for detailed quantification of histological marker staining within cells and tissues, is pleased to announce it will be a principal sponsor of the forthcoming Tumor Models conference to be held in Boston, MA on the 23-25th July.

24 Jul 2013

Efficacy News and Research

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Naurex receives new U.S. patent for its lead compound, GLYX-13

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Rapamycin extends mice lifespan but has limited effects on aging

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

New technology enables all of the world's crops to take nitrogen from the air

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Silk implants placed in brain of animals may help stop progression of epilepsy

Novo Solutions MD announces releases of NovoScarMD scar cream

Studies support use of EOS 3D imaging system in assessing impact of bracing for AIS

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

New procedures to improve quality and usefulness of preclinical efficacy studies

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News